AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$57.10
neg -1.44
-2.46%
Today's Range: 56.33 - 58.49 | ABBV Avg Daily Volume: 11,907,200
Last Update: 04/01/15 - 4:01 PM EDT
Volume: 14,900,449
YTD Performance: -10.54%
Open: $58.47
Previous Close: $58.54
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,886,909
Market Cap: 92,726,563,763
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 7 8
Moderate Buy 0 0 0 0
Hold 3 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.60 1.67 1.73 1.55
Latest Dividend: 0.51
Latest Dividend Yield: 3.50%
Dividend Ex-Date: 04/13/15
Price Earnings Ratio: 52.95
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
52.95 52.90 27.63
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-10.54% 13.89% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.84 $1.08 $4.34 $5.10
Number of Analysts 7 6 8 8
High Estimate $0.86 $1.10 $4.42 $5.33
Low Estimate $0.81 $1.03 $4.22 $4.77
Prior Year $0.72 $0.82 $3.32 $4.34
Growth Rate (Year over Year) 16.27% 31.10% 30.65% 17.67%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 31, 2015 | 11:33 AM EDT

Combined Heinz-Kraft heads a long second-quarter list.

By

Jim Cramer

 | Mar 27, 2015 | 12:00 PM EDT

You can't help but feel better about both groups.

By

Jim Cramer

 | Mar 27, 2015 | 5:21 AM EDT

If there is no catalyst, I'd join those who sell on a bounce.

By

Jim Cramer

 | Mar 25, 2015 | 6:23 PM EDT

This sector could see some real damage.

By

Jim Cramer

 | Mar 21, 2015 | 2:30 PM EDT

Own them, or take something off the table?

By

Jim Cramer

 | Mar 19, 2015 | 6:52 PM EDT

Market backtracks on skepticism over biotechs.

By

Jim Cramer

 | Mar 16, 2015 | 11:57 AM EDT

It shouldn't be possible, but it never seems too late to get in.

By

Bret Jensen

 | Mar 6, 2015 | 6:52 AM EST
I am happy to be standing in for Doug Kass today on the Daily Diary.
By

Jim Cramer

 | Mar 5, 2015 | 4:22 PM EST

Stocks that stabilized yesterday were terrific today.

By

Jim Cramer

 | Mar 5, 2015 | 1:20 PM EST

Kroger is a good example of execution.

Apologies to Mad Magazine!

...

The S&P 500 Index and the DJIA held their March lows today and reversed early session ...

Only $150 million to sell market on close.

Market has cut losses from lows in response triggered by poor auto sales, manufacturing &a...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.